Diligence memo · auto-generated · as of July 3, 2026
Atacama Therapeutics, Inc.
Atacama Therapeutics, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Atacama Therapeutics, Inc. operates in Pharma, based in WELLESLEY.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Atacama Therapeutics, Inc. has raised $830K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $830K on 2024-04-26.
Most recent recorded round closed around 2024-04-26.
Valuation (modeled)modeled
Provath models Atacama Therapeutics, Inc. at approximately $4.2M (range $465K–$15M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.75× the median modeled value of Pre-Seed Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.2 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 33% of Pharma peers (310 compared).
Modeled value ranks above 26% of those peers.
Closest niche peers: Acanna Therapeutics, Inc., Neural Therapeutics Inc., Insignis Therapeutics Inc., Pharma Acuity, Inc., Arena Therapeutics OpCo, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.